FDA
-
-
-
-
-
-
-
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
-
-
-
-
-
-
-
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
-
-
-
-
-
-
-
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
-
-
-
-
-
-
-
Emergent BioSolutions gets $56 million U.S. contract for smallpox vaccine
-
-
-
-
-
-
-
Emergent BioSolutions (EBS) Expands NARCANDirect to Offer KLOXXADO Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
-
-
-
-
-
-
-
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
-
-
-
-
-
-
-
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
-
330,004 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

